Tag Archives: FDA

Mvasi by Amgen is the First FDA Approved Cancer Biosimilar

FDA Approves the First Cancer Biosimilar Mvasi by Amgen is Hitting the US Market   Yesterday the FDA announced that Amgens biosimilar to Avastin, known as Mvasi (bevacizumab-awwb) was approved for five different types of cancer: Non-squamous non-small cell lung cancer (NSCLC) – in combination with chemotherapy Metastatic colorectal cancer (mCRC) – in combination with chemotherapy Glioblastoma Metastatic renal […]

Meet us at FACE London June 2016

We are excited to present at FACE London this year, held at the QEII Centre, Westminster London from 15th-18th June. Dr Kelly will open the Business Agenda on Friday morning at 9:30am with a talk entitled “Vertical growth on a global scale: how cosmeceuticals and disruptive tech are driving the market” She will present new […]

Inflectra (infliximab-dyyb), 2nd Biosimilar Approved in US

The Biosimilar market got a significant boost this week as the FDA approved Inflectra (infliximab-dyyb) which is a biosimilar to Janssen Biotech’s Remicade (infliximab) on April 5th 2016. Celltrion manufactures Inflectra for Hospira, and is now approved for the following indications in the US: Crohn’s disease Ulcerative colitis Rheumatoid arthritis in combination with methotrexate Ankylosing spondylitis […]